Neofordex

RSS

dexamethasone

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Neofordex. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Neofordex.

For practical information about using Neofordex, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 23/01/2023

Authorisation details

Product details
Name
Neofordex
Agency product number
EMEA/H/C/004071
Active substance
dexamethasone
International non-proprietary name (INN) or common name
dexamethasone
Therapeutic area (MeSH)
Multiple Myeloma
Anatomical therapeutic chemical (ATC) code
H02AB02
Publication details
Marketing-authorisation holder
Laboratoires CTRS 
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
16/03/2016
Contact address

Laboratoires CTRS
16 Rue Montrosier
92200 Neuilly-sur-Seine
France

Product information

18/01/2023 Neofordex - EMEA/H/C/004071 - IAIN/0020/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Corticosteroids for systemic use

Therapeutic indication

Treatment of multiple myeloma.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings